1. Home
  2. ITRM vs WAL Comparison

ITRM vs WAL Comparison

Compare ITRM & WAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITRM
  • WAL
  • Stock Information
  • Founded
  • ITRM 2015
  • WAL 1994
  • Country
  • ITRM Ireland
  • WAL United States
  • Employees
  • ITRM N/A
  • WAL N/A
  • Industry
  • ITRM Biotechnology: Pharmaceutical Preparations
  • WAL Major Banks
  • Sector
  • ITRM Health Care
  • WAL Finance
  • Exchange
  • ITRM Nasdaq
  • WAL Nasdaq
  • Market Cap
  • ITRM 37.7M
  • WAL 7.3B
  • IPO Year
  • ITRM 2018
  • WAL 2005
  • Fundamental
  • Price
  • ITRM $1.03
  • WAL $64.90
  • Analyst Decision
  • ITRM Strong Buy
  • WAL Strong Buy
  • Analyst Count
  • ITRM 1
  • WAL 15
  • Target Price
  • ITRM $5.00
  • WAL $96.40
  • AVG Volume (30 Days)
  • ITRM 316.7K
  • WAL 1.5M
  • Earning Date
  • ITRM 05-12-2025
  • WAL 04-21-2025
  • Dividend Yield
  • ITRM N/A
  • WAL 2.36%
  • EPS Growth
  • ITRM N/A
  • WAL 8.41
  • EPS
  • ITRM N/A
  • WAL 7.09
  • Revenue
  • ITRM N/A
  • WAL $3,016,200,000.00
  • Revenue This Year
  • ITRM N/A
  • WAL $13.39
  • Revenue Next Year
  • ITRM $150.10
  • WAL $9.74
  • P/E Ratio
  • ITRM N/A
  • WAL $9.09
  • Revenue Growth
  • ITRM N/A
  • WAL 17.96
  • 52 Week Low
  • ITRM $0.81
  • WAL $56.70
  • 52 Week High
  • ITRM $3.02
  • WAL $98.10
  • Technical
  • Relative Strength Index (RSI)
  • ITRM 29.22
  • WAL 39.60
  • Support Level
  • ITRM $1.05
  • WAL $60.01
  • Resistance Level
  • ITRM $1.16
  • WAL $67.03
  • Average True Range (ATR)
  • ITRM 0.08
  • WAL 4.78
  • MACD
  • ITRM -0.01
  • WAL 0.18
  • Stochastic Oscillator
  • ITRM 7.41
  • WAL 37.96

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

About WAL Western Alliance Bancorporation (DE)

Western Alliance Bancorporation is a Las Vegas-based holding company with regional banks operating in Nevada, Arizona, and California. The bank offers retail banking services and focuses on mortgages for retail customers and commercial loans. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.

Share on Social Networks: